E. coli and colon cancer: Is mutY a culprit?

Cancer Letters

Volumn 341, Issue 2, 2013, Pages 127-131

  Khan, Abdul Arif ^a,b   Cash, Phillip ^c  

^a Cancer Hospital and Research Institute   (India)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Carcinogenesis; Chronic inflammation; E. coli; MutY; MUTYH

Indexed keywords

BACTERIAL TOXIN; CYCLOMODULIN; CYTOTOXIC NECROTIZING FACTOR; DNA GLYCOSYLASE MUTY; UNCLASSIFIED DRUG; DNA GLYCOSYLTRANSFERASE; ESCHERICHIA COLI PROTEIN;

BACTERIAL METABOLISM; CANCER CONTROL; CANCER GROWTH; COLON CANCER; COLON CARCINOGENESIS; COLORECTAL CANCER; DISEASE ASSOCIATION; DNA METHYLATION; ENTEROPATHOGENIC ESCHERICHIA COLI; EPIGENETICS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; GENE FUNCTION; HORIZONTAL GENE TRANSFER; HUMAN; INFECTION CONTROL; MISMATCH REPAIR; MUTY GENE; NONHUMAN; PRIORITY JOURNAL; SEQUENCE HOMOLOGY; SHORT SURVEY; SIGNAL TRANSDUCTION; ANIMAL; BIOLOGICAL MODEL; COLORECTAL TUMOR; DNA REPAIR; GENETICS; HOST PATHOGEN INTERACTION; INTESTINE MUCOSA; METABOLISM; MICROBIOLOGY; MOUSE; PATHOLOGY; PHYSIOLOGY;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; MUS;

ANIMALS; COLORECTAL NEOPLASMS; DNA GLYCOSYLASES; DNA REPAIR; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; HOST-PATHOGEN INTERACTIONS; INTESTINAL MUCOSA; MICE; MODELS, GENETIC;

EID: 84887171375     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.08.003     Document Type: Review

References (47)

1. Arthur J.C., Perez-Chanona E., Muhlbauer M., Tomkovich S., Uronis J.M., Fan T.J., Campbell B.J., Abujamel T., Dogan B., Rogers A.B., Rhodes J.M., Stintzi A., Simpson K.W., Hansen J.J., Keku T.O., Fodor A.A., Jobin C. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 2012, 338:120-123.
2. Wogan G.N., Dedon P.C., Tannenbaum S.R., Fox J.G. Infection, inflammation and colon carcinogenesis. Oncotarget 2012, 3:737-738.
3. Khan A.A., Shrivastava A., Khurshid M. Normal to cancer microbiome transformation and its implication in cancer diagnosis. Biochim. Biophys. Acta 1826, 2012:331-337.
4. Friswell M., Campbell B., Rhodes J. The role of bacteria in the pathogenesis of inflammatory bowel disease. Gut Liver 2010, 4:295-306.
5. Ekbom A., Helmick C., Zack M., Adami H.O. Ulcerative colitis and colorectal cancer. A population-based study. N. Engl. J. Med. 1990, 323:1228-1233.
6. Gillen C.D., Andrews H.A., Prior P., Allan R.N. Crohn's disease and colorectal cancer. Gut 1994, 35:651-655.
7. Collins D., Hogan A.M., Winter D.C. Microbial and viral pathogens in colorectal cancer. Lancet Oncol. 2011, 12:504-512.
8. Antonic V., Stojadinovic A., Kester K.E., Weina P.J., Brucher B.L., Protic M., Avital I., Izadjoo M. Significance of infectious agents in colorectal cancer development. J. Cancer 2013, 4:227-240.
9. Martin H.M., Campbell B.J., Hart C.A., Mpofu C., Nayar M., Singh R., Englyst H., Williams H.F., Rhodes J.M. Enhanced Escherichia coli adherence and invasion in Crohn's disease and colon cancer. Gastroenterology 2004, 127:80-93.
10. Buc E., Dubois D., Sauvanet P., Raisch J., Delmas J., Darfeuille-Michaud A., Pezet D., Bonnet R. High prevalence of mucosa-associated Escherichia coli producing cyclomodulin and genotoxin in colon cancer. PLoS One 2013, 8:e56964.
11. Fiorentini C., Matarrese P., Straface E., Falzano L., Fabbri A., Donelli G., Cossarizza A., Boquet P., Malorni W. Toxin-induced activation of rho GTP-binding protein increases Bcl-2 expression and influences mitochondrial homeostasis. Exp. Cell. Res. 1998, 242:341-350.
12. Oswald E., Sugai M., Labigne A., Wu H.C., Fiorentini C., Boquet P., O'Brien A.D. Cytotoxic necrotizing factor type 2 produced by virulent Escherichia coli modifies the small GTP-binding proteins Rho involved in assembly of actin stress fibers. Proc. Natl. Acad. Sci. USA 1994, 91:3814-3818.
13. Mager D.L. Bacteria and cancer: cause, coincidence or cure? A review. J. Trans. Med. 2006, 4:14.
14. Taieb F., Nougayrede J.P., Watrin C., Samba-Louaka A., Oswald E. Escherichia coli cyclomodulin Cif induces G2 arrest of the host cell cycle without activation of the DNA-damage checkpoint-signalling pathway. Cell. Microbiol. 2006, 8:1910-1921.
15. Marches O., Ledger T.N., Boury M., Ohara M., Tu X., Goffaux F., Mainil J., Rosenshine I., Sugai M., De Rycke J., Oswald E. Enteropathogenic and enterohaemorrhagic Escherichia coli deliver a novel effector called Cif, which blocks cell cycle G2/M transition. Mol. Microbiol. 2003, 50:1553-1567.
16. Nougayrede J.P., Taieb F., De Rycke J., Oswald E. Cyclomodulins: bacterial effectors that modulate the eukaryotic cell cycle. Trends. Microbiol. 2005, 13:103-110.
17. Edgar B.A., Orr-Weaver T.L. Endoreplication cell cycles: more for less. Cell 2001, 105:297-306.
18. Charpentier X., Oswald E. Identification of the secretion and translocation domain of the enteropathogenic and enterohemorrhagic Escherichia coli effector Cif, using TEM-1 beta-lactamase as a new fluorescence-based reporter. J. Bacteriol. 2004, 186:5486-5495.
19. Haghjoo E., Galan J.E. Salmonella typhi encodes a functional cytolethal distending toxin that is delivered into host cells by a bacterial-internalization pathway. Proc. Natl. Acad. Sci. USA 2004, 101:4614-4619.
20. Toth I., Herault F., Beutin L., Oswald E. Production of cytolethal distending toxins by pathogenic Escherichia coli strains isolated from human and animal sources: establishment of the existence of a new CDT variant (Type IV). J. Clin. Microbiol. 2003, 41:4285-4291.
21. Lara-Tejero M., Galan J.E. CdtA, CdtB, and CdtC form a tripartite complex that is required for cytolethal distending toxin activity. Infect. Immun. 2001, 69:4358-4365.
22. Ge Z., Rogers A.B., Feng Y., Lee A., Xu S., Taylor N.S., Fox J.G. Bacterial cytolethal distending toxin promotes the development of dysplasia in a model of microbially induced hepatocarcinogenesis. Cell. Microbiol. 2007, 9:2070-2080.
23. Maddocks O.D., Short A.J., Donnenberg M.S., Bader S., Harrison D.J. Attaching and effacing Escherichia coli downregulate DNA mismatch repair protein in vitro and are associated with colorectal adenocarcinomas in humans. PLoS One 2009, 4:e5517.
24. Wheeler L.A., Soderberg F.B., Goldman P. The reduction of N-hydroxy-4-acetylaminobiphenyl by the intestinal microflora of the rat. Cancer Res. 1975, 35:2962-2968.
25. Khan A.A., Khurshid M., Khan S., Alshamsan A. Gut microbiota and probiotics: current status and their role in cancer therapeutics. Drug Dev. Res. 2013, 10.1002/ddr.21087.
26. Swidsinski A., Khilkin M., Kerjaschki D., Schreiber S., Ortner M., Weber J., Lochs H. Association between intraepithelial Escherichia coli and colorectal cancer. Gastroenterology 1998, 115:281-286.
27. Lu H., Ouyang W., Huang C. Inflammation, a key event in cancer development. Mol. Cancer. Res. 2006, 4:221-233.
28. Markowitz S.D., Bertagnolli M.M. Molecular origins of cancer: molecular basis of colorectal cancer. N. Engl. J. Med. 2009, 361:2449-2460.
29. Poulsen M.L., Bisgaard M.L. MUTYH associated polyposis (MAP). Curr. Genomics. 2008, 9:420-435.
30. Bougatef K., Marrakchi R., Kourda N., Ben Lahely Y.B., Jileni S.B., El Khil H.K., Soubrier F., Ben Ammar Elgaaied A. Somatic mutation of MutYH in Tunisian patients with sporadic colorectal cancer. J. Clin. Lab. Anal. 2007, 21:372-374.
31. Dunning Hotopp J.C., Clark M.E., Oliveira D.C., Foster J.M., Fischer P., Munoz Torres M.C., Giebel J.D., Kumar N., Ishmael N., Wang S., Ingram J., Nene R.V., Shepard J., Tomkins J., Richards S., Spiro D.J., Ghedin E., Slatko B.E., Tettelin H., Werren J.H. Widespread lateral gene transfer from intracellular bacteria to multicellular eukaryotes. Science 2007, 317:1753-1756.
32. Editorial, Focus on host subversion, Nat. Cell. Biol. 11 (2009) 509.
33. Jenkins M.A., Croitoru M.E., Monga N., Cleary S.P., Cotterchio M., Hopper J.L., Gallinger S. Risk of colorectal cancer in monoallelic and biallelic carriers of MYH mutations: a population-based case-family study. Cancer Epidemiol. Biomarkers Prev. 2006, 15:312-314.
34. Maddocks O.D., Scanlon K.M., Donnenberg M.S. An Escherichia coli effector protein promotes host mutation via depletion of dna mismatch repair proteins. MBio 2013, 4.
35. Minarovits J. Microbe-induced epigenetic alterations in host cells: the coming era of patho-epigenetics of microbial infections. A review. Acta Microbiol. Immunol. Hung. 2009, 56:1-19.
36. Gronbaek K., Hother C., Jones P.A. Epigenetic changes in cancer. Apmis 2007, 115:1039-1059.
37. Sassen S., Miska E.A., Caldas C. MicroRNA: implications for cancer. Virchows Arch. 2008, 452:1-10.
38. Masotti A. Interplays between gut microbiota and gene expression regulation by miRNAs. Front. Cell. Infect. Microbiol. 2012, 2:137.
39. Tili E., Michaille J.J., Cimino A., Costinean S., Dumitru C.D., Adair B., Fabbri M., Alder H., Liu C.G., Calin G.A., Croce C.M. Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-alpha stimulation and their possible roles in regulating the response to endotoxin shock. J. Immunol. 2007, 179:5082-5089.
40. Meijer K., de Vos P., Priebe M.G. Butyrate and other short-chain fatty acids as modulators of immunity: what relevance for health?. Curr. Opin. Clin. Nutr. Metab. Care 2010, 13:715-721.
41. Conterno L., Fava F., Viola R., Tuohy K.M. Obesity and the gut microbiota: does up-regulating colonic fermentation protect against obesity and metabolic disease?. Genes. Nutr. 2011, 6:241-260.
42. Baylin S.B., Esteller M., Rountree M.R., Bachman K.E., Schuebel K., Herman J.G. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum. Mol. Genet. 2001, 10:687-692.
43. Zitt M., Muller H.M. DNA methylation in colorectal cancer-impact on screening and therapy monitoring modalities?. Dis. Markers 2007, 23:51-71.
44. Paschos K., Allday M.J. Epigenetic reprogramming of host genes in viral and microbial pathogenesis. Trends Microbiol. 2010, 18:439-447.
45. Dean P. Functional domains and motifs of bacterial type III effector proteins and their roles in infection. FEMS Microbiol. Rev. 2011, 35:1100-1125.
46. Tran E.J., Wente S.R. Dynamic nuclear pore complexes: life on the edge. Cell 2006, 125:1041-1053.
47. Kaczmarczyk S.J., Sitaraman K., Hill T., Hartley J.L., Chatterjee D.K. Tus, an Escherichia coli protein, contains mammalian nuclear targeting and exporting signals. PLoS One 2010, 5:e8889.